Figure 3

Bicalutamide treatment inhibited the growth of sub-cutaneous (SC) PCSD1 tumors more than intra-femoral (IF) PCSD1 tumors. PCSD1 xenograft cells were directly injected either sub-cutaneously (SC) or intra-femorally (IF) into Rag2 ^−/− ;γ _c ^−/− mice. A.) Wet tumor weight of bicalutamide treated SC tumors was reduced. B.) Bicalutamide reduced average wet SC tumor weight by half. C.) Bicalutamide (red line) suppressed PCSD1 tumor growth in mice with sub-cutaneously transplanted tumors compared to vehicle treatment (blue line). D.) Bicalutamide (red line) did not significantly suppress PCSD1 tumor growth in mice with intra-femorally transplanted tumors compared to vehicle treatment (blue line). Length and width of tumors were measured in mm using calipers and used to calculate tumor volume. Vehicle control (blue, SC n = 4 mice, IF n = 5), Bicalutamide 50 mg/kg/day, (red, SC n = 5, IF n = 5) E.) Waterfall plot of percent change in final tumor volume at termination, Day 18, from baseline, the tumor volume treatment Day 1. Blue bars are for individual mice treated with vehicle control, Red bars are for individual mice treated with bicalutamide. Error bars denote standard error.